We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Favorable earnings estimate revisions are key for a stock to move higher, precisely where the Zacks Rank comes into play.
The Zacks Rank uses four factors related to earnings estimates to classify stocks into five groups, ranging from ‘Strong Buy’ to ‘Strong Sell.’ Importantly, it allows individual investors to take advantage of trends in earnings estimate revisions and benefit from the power of institutional investors.
Stride is a premier provider of K-12 education for students, schools, and districts, including career learning services through middle and high school curricula. The stock sports a Zacks Rank #1 (Strong Buy), with earnings expectations higher across the board.
Image Source: Zacks Investment Research
Strong quarterly results have aided share performance year-to-date, with LRN shares adding 16% in value in 2024 relative to the S&P 500’s 12% gain. In fact, the company has exceeded the Zacks Consensus EPS estimate by an average of 42% across its last four releases.
Operational efficiencies have allowed the company to enjoy notable margin expansion, improving profitability considerably. Please note that the chart below is on a trailing twelve-month basis.
Image Source: Zacks Investment Research
And the company’s growth is expected to remain robust, with consensus expectations for its current fiscal year suggesting 53% EPS growth on 10% higher sales.
Interactive Brokers Shares Up +50% YTD
IBKR shares have been notably strong year-to-date, gaining +50% compared to the S&P 500’s impressive +12% gain. The company’s latest set of quarterly results brought post-earnings positivity, with it exceeding both earnings and revenue expectations.
Analysts have raised their earnings expectations across the board, landing the stock into a Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
The results snapped a streak of mixed earnings results, with earnings and revenue growing by 21% and 25%, respectively. IBKR’s revenue growth has remained strong, with the company posting double-digit percentage year-over-year sales growth rates in each of its last seven periods.
Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Haemonetics’ Sales Continue to Grow
Haemonetics provides blood management solutions to customers encompassing blood and plasma collectors, hospitals, and health care providers globally. Analysts have raised their expectations higher, landing the stock into a Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Like IKBR, the company has been enjoying notable revenue growth, posting double-digit percentage year-over-year sales growth in nine of its last ten periods. And growth is expected to remain solid, with consensus expectations for its current fiscal year suggesting 15% earnings growth on 7% higher sales.
Image Source: Zacks Investment Research
Bottom Line
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
All three stocks above – Stride (LRN - Free Report) , Interactive Brokers (IBKR - Free Report) , and Haemonetics (HAE - Free Report) – presently sport a Zacks Rank #1 (Strong Buy), reflecting upward trending earnings estimate revisions.
Visit Zacks Rank Education to learn more about using this proven system for market-beating gains.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
These 3 Companies Boast Bright Outlooks
Favorable earnings estimate revisions are key for a stock to move higher, precisely where the Zacks Rank comes into play.
The Zacks Rank uses four factors related to earnings estimates to classify stocks into five groups, ranging from ‘Strong Buy’ to ‘Strong Sell.’ Importantly, it allows individual investors to take advantage of trends in earnings estimate revisions and benefit from the power of institutional investors.
Let’s examine a few highly ranked stocks, including Stride (LRN - Free Report) , Interactive Brokers (IBKR - Free Report) , and Haemonetics (HAE - Free Report) .
Stride Enjoys Profitability Boost
Stride is a premier provider of K-12 education for students, schools, and districts, including career learning services through middle and high school curricula. The stock sports a Zacks Rank #1 (Strong Buy), with earnings expectations higher across the board.
Image Source: Zacks Investment Research
Strong quarterly results have aided share performance year-to-date, with LRN shares adding 16% in value in 2024 relative to the S&P 500’s 12% gain. In fact, the company has exceeded the Zacks Consensus EPS estimate by an average of 42% across its last four releases.
Operational efficiencies have allowed the company to enjoy notable margin expansion, improving profitability considerably. Please note that the chart below is on a trailing twelve-month basis.
Image Source: Zacks Investment Research
And the company’s growth is expected to remain robust, with consensus expectations for its current fiscal year suggesting 53% EPS growth on 10% higher sales.
Interactive Brokers Shares Up +50% YTD
IBKR shares have been notably strong year-to-date, gaining +50% compared to the S&P 500’s impressive +12% gain. The company’s latest set of quarterly results brought post-earnings positivity, with it exceeding both earnings and revenue expectations.
Analysts have raised their earnings expectations across the board, landing the stock into a Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
The results snapped a streak of mixed earnings results, with earnings and revenue growing by 21% and 25%, respectively. IBKR’s revenue growth has remained strong, with the company posting double-digit percentage year-over-year sales growth rates in each of its last seven periods.
Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Haemonetics’ Sales Continue to Grow
Haemonetics provides blood management solutions to customers encompassing blood and plasma collectors, hospitals, and health care providers globally. Analysts have raised their expectations higher, landing the stock into a Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Like IKBR, the company has been enjoying notable revenue growth, posting double-digit percentage year-over-year sales growth in nine of its last ten periods. And growth is expected to remain solid, with consensus expectations for its current fiscal year suggesting 15% earnings growth on 7% higher sales.
Image Source: Zacks Investment Research
Bottom Line
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
All three stocks above – Stride (LRN - Free Report) , Interactive Brokers (IBKR - Free Report) , and Haemonetics (HAE - Free Report) – presently sport a Zacks Rank #1 (Strong Buy), reflecting upward trending earnings estimate revisions.
Visit Zacks Rank Education to learn more about using this proven system for market-beating gains.